Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- STATISTICS
March 20, 2006
- SEMINAR
March 20, 2006
- Major Products, Major Firms Hit Hard: NHI Price Revision
March 20, 2006
- HUMAN RESOURCES
March 20, 2006
- Proposed Policy on Return of Goods Approved by Ryukaikon
March 13, 2006
- Korosho Wants to See All Original Brands Available at the Same Strengths
March 13, 2006
- REGULATORY NEWS IN BRIEF
March 13, 2006
- Hayashibara to Develop Alzheimer's Disease Vaccine
March 13, 2006
- Explanatory Meeting on JapicCTI
March 13, 2006
- ＜JCROA Seminar＞Collaborative Int'l Trials Remain Risky: Dr Iwasaki of EFPIA
March 13, 2006
- GENERICS NEWS IN BRIEF
March 13, 2006
- R&D NEWS IN BRIEF
March 13, 2006
- Eisai Aims at \1 Tril. Sales in FY2011
March 13, 2006
- SELF-MEDICATION NEWS IN BRIEF
March 13, 2006
- Mr Iwasaki to Implement Reform through Dialogues with Employees: Pfizer
March 13, 2006
- OPINION
March 13, 2006
- Takeda Promoting Basen OD Tables to Win Market Competition
March 13, 2006
- JPA Holds 100th Assembly of House of Delegates
March 13, 2006
- Norvasc Was Most-prescribed Drug in 2005: IMS Japan
March 13, 2006
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 13, 2006
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…